References
- Baker J. F., Wohlford J. G., Bradbury B. J., With P. W. Mammalian metabolism of phencyclidine. Journal of Medicinal Chemistry 1981; 24: 666–669
- Brady J. F., Dokko J., DiStefano E. W., Cho A. K. Mechanism-based inhibition of cytochrome P450 (P450) by heterocyclic analogs of phencyclidine (PCP). Drug Metabolism and Disposition 1987; 15: 648–652
- Budd R. D. PHP, a new drug of abuse. New England Journal of Medicine 1980; 588, 4 September
- Cho A. K., Hallström G., Matsumoto R. M., Kammerer R. C. The metabolism of the piperidine ring of phencyclidine,. Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications (Joint French-U.S. Seminar on the Chemistry, Pharmacology, Toxicology, Therapy and Drug Abuse Aspects of Arylcyclohexylamines, Montpellier), J.-M. Kamenka, E. F. Domino, P. Geneste. NPP Books, Ann Arbor, MI 1983; 205–214
- Cohen L. S., Gosenfeld L., Wilkins J., Kammerer R. C., Tachiki K. Demonstration of an amino acid metabolite of phencyclidine. New England Journal of Medicine 1982; 306: 1427–1428
- Dixon W. J. BMDP Statistical Software Manual. University of California Press, Los Angeles, CA 1988; 389–418
- Gole D. J., Pirat J. L., Domino E. F. New aspects of phencyclidine (PCP) metabolism,. Sigma and Phencyclidine-like Compounds as Molecular Probes in Biology, E. F. Domino, J. M. Kamenka. NPP Books, Ann Arbor, MI 1988; 625–642
- Hallström G., Kammerer R. C., Nguyen C. H., Schmitz D. A., DiStefano E. W., Cho A. K. Phencyclidine metabolism in vitro: the formation of a carbinolamine and its metabolites by rabbit liver preparations. Drug Metabolism and Disposition 1983; 11: 47–53
- Rogawski M. A., Thurkauf A., Yamaguchi S., Rice K. C., Jacobson A. E., Mattson M. V. Anticonvulsant activities of 1-phenylcyclohexylamine and its conformationally restricted analog 1,1-pentamethylenetrahydroisoquinoline. Journal of Pharmacology and Experimental Therapeutics 1989; 249: 708–712
- Schenkamn J. B., Remmer H., Estabrook R. W. Spectral studies of drug interaction with hepatic microsomal cytochrome. Molecular Pharmacology 1967; 3: 113–123
- Shannon H. E. Evaluation of phencyclidine analogs on the basis of the discriminative stimulus properties in the rat. Journal of Pharmacology and Experimental Therapeutics 1981; 216: 543–551
- Smialek J. E., Montforte J. R., Gault R., Spitz W. U. Cyclohexamine (“Rocket Fuel”)-phencyclidines potent analog. Journal of Analytical Toxicology 1979; 3: 209–212
- Vaupel D. B., McCoun D., Cone E. J. Phencyclidine analogs and precursors: Rotarod and lethal dose studies in the mouse. Journal of Pharmacology and Experimental Therapeutics 1984; 230: 20–27
- Weber E., Sonders M., Quarum M., McLean S., Pou S., Keana J. F. W. 1,3-Di(2-[5,-3H]-toly)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proceedings of the National Academy of Sciences, USA 1986; 83: 8784–8788
- Wong E. H. F., Knight A. R., Woodruff G. N. 3H-MK801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. Journal of Neurochemistry 1988; 50: 274–281